Neurodegenerative Disease Treatment
Market Drivers:-
Major driver for growth of the
global Neurodegenerative
Disease Treatment Market is robust pipeline of drugs. For instance,
FlorbetapirF 18 sponsored by Avid Radiopharmaceuticals, a pharmaceutical
company focused on improving clinical development of drugs completed phase 2
clinical trials in 2017. This drug is used as biomarkers for neurodegenerative
diseases such as Alzheimer’s disease. F 18 T807 sponsored by Washington school
of medicine is in phase 2 clinical trials since 2015. This drug is used to
treat Amyotrophic Lateral Sclerosis (ALS).
Mergers and acquisitions by
market players are expected to drive the neurodegenerative disease treatment
market growth. For instance, in June 2018, Alexion Pharmaceuticals Inc.,
US-based global biopharmaceutical company merged with Complement Pharma,
Netherlands-based biotech company to develop preclinical C-6 complement
inhibitor CP010 for neurodegenerative disorders such as Parkinson’s disease and
Amyotrophic Lateral Sclerosis (ALS). C6 inhibition prevents the formation of
Membrane attack complex (MAC), a complex of terminal complement proteins, which
has potential to treat a variety of central nervous system disorders.
Launch of new drugs and high
prevalence of neurodegenerative diseases are expected to support the growth in
neurodegenerative disease treatment market size. For instance, in 2018, ArunA
Biomedical launched exosome (Cell derived vesicles that are present in blood)
biologic to treat Central Nervous System (CNS) and neurodegenerative diseases.
Exosome biologics are used in treatment of CNS and neurodegenerative diseases
such as Alzheimer’s disease, Parkinson’s disease, and Amyotrophic Lateral
Sclerosis (ALS).
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/1860
Neurodegenerative diseases
involves progressive loss of function and structure of neurons, which sometimes
also includes death of neurons. Major cause of neurodegeneration is deposition
of toxic protein substance in the brain, which hinders the function of
mitochondria in the brain. Some of the neurodegenerative diseases are caused by
genetic mutations due to expansion of CAG trinucleotide and poly Q tract, for
instance, Huntington’s disease and spinocerebellar ataxias. Some
neurodegenerative diseases are caused due to aggregation of misfolded proteins,
for instance Alzheimer’s disease, Huntington disease, and Parkinson’s disease.
One of the common factors for cell death in neurodegeneration is intrinsic
mitochondrial apoptotic pathway, for instance Amyotrophic lateral sclerosis.
Alzheimer’s disease is caused due to aggregation of misfolded protein.
Parkinson’s disease affects the central nervous system by abnormal accumulation
of protein alpha-synuclein bound to ubiquitin in the damaged cells.
Huntington’s disease is a genetic disorder that causes breakdown of nerve cells
in the brain.
Increasing research for
neurodegenerative diseases treatment is expected to boost growth of
neurodegenerative disease treatment market. For instance, E-Scape Bio, a
biopharmaceutical company, would be investing more than US$ 63 million on
research for treatment of Parkinson’s and Alzheimer’s disease from 2017 for
development for new drug.
Lack of reimbursement policies
provided by the government and hospitals for the treatment of neurodegenerative
diseases such as Alzheimer’s disease, Parkinson’s disease, and Amyotrophic
Lateral Sclerosis (ALS) are restraining growth of the market.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/neurodegenerative-disease-treatment-market-1860
Neurodegenerative Disease
Treatment Market Regional Analysis:-
North America is expected to hold
dominant position in global neurodegenerative disease treatment market due to
the strategic mergers and acquisitions among key players. For instance, in
2018, Abbvie Inc. a biopharmaceutical company merged with Voyager Therapeutics,
a gene therapy developing company to develop gene therapies to treat
Alzheimer’s disease. In 2014, Bristol Myers Squibb, an American pharmaceutical
company acquired iPierian Inc. a drug discovery platform that develops
therapies for neurodegenerative diseases. Bristol Myers Squibb acquired
iPierian’s leading drug IPN007. IPN007 is a monoclonal antibody to treat
progressive supranuclear palsy (a medical condition in which consists of
deterioration of cells in various areas of brain that control thinking and body
movement).
Europe neurodegenerative disease
treatment market is expected to witness a significant growth due to increasing
prevalence of neurodegenerative diseases. According to a survey conducted by
Parkinson Association of the Carolinas in 2016, more than 60000 new people in
the U.S. are diagnosed with Parkinson’s disease annually. Therefore, increasing
number of neurodegenerative disorders is in turn driving growth of the
neurodegenerative disease treatment market.
Neurodegenerative Disease
Treatment Market Key Players:-
Key players operating in global
neurodegenerative disease treatment market include Novartis AG, Pfizer Inc.,
Merck Serono, Biogen Inc., Teva Pharmaceutical Industries Ltd., UCB, C.H.
Boehringer Sohn AG & Co. KG, Sanofi S.A., GlaxoSmithKline, and Neuro-Hitech
Inc.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/1860
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S. Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment